Bayer Yakuhin Transfers Fludara Rights To Genzyme Japan
This article was originally published in PharmAsia News
Bayer Yakuhin signed an agreement to transfer Fludara (fludarabine) rights to Genzyme Japan starting July 1
You may also be interested in...
The EU’s upcoming pharma strategy offers an important opportunity for change, according to Medicines for Europe. The off-patent industry body has set out five key issues that should be priorities for the EU Commission.
The EU’s IVD Regulation is going to apply just a year later than the EU’s MDR. Where are the gaps and how can industry manage the IVD notified body shortage?
The dangers of a hard Brexit, a welcome delay to the EU Medical Devices Regulation and the impact of the coronavirus on the German OTC market all feature in this exclusive HBW Insight catch up with Germany's self-medication industry association, the BAH.